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 Despite the improvement of antibiotics prophylaxis, surgical technique, and 
immunosuppressive regimen following kidney transplantation (KT), urinary tract infections 
(UTIs) remain the most common infectious complication that can substantially interfere 
with the patients’ quality of life.  Studies within the last decade have reported the incidence 
of UTIs ranging from 25% to 75%, which varies widely likely due to differences in definition, 
diagnostic criteria, study design, and length of observation].  It has been reported that 
female sex, older age of the recipient, acute rejection episodes, and cadaveric donor were 
associated with higher risks of UTI.  In patients with such an immunologically impaired 
condition, components of the adaptive cellular immunity are significantly reduced; however, 
innate components and humoral factors with probable defense mechanism remain relatively 
stable. 
We have recently proven that the Fc gamma receptor (FcγR) single-nucleotide 
polymorphisms (SNPs) in liver transplant recipients were greatly associated with the 
susceptibility to post-transplant bloodstream infection.  In the current study, we 
investigated the impact of SNPs in C1QA [276 A/G], FCGR2A [131 H/R], and FCGR3A [158 
F/V] genes on the development of infectious complications after KT. 
 The SNPs of C1QA [276 A/G], FCGR2A [131 H/R], and FCGR3A [158 F/V], genes 
encoding the FcγR, were analyzed in 81 KT recipients in relation to the occurrences of 
postoperative infectious complications within 30 days after KT.  Among all subjects, 31 
(38.3 %) recipients experienced UTI episode within 1 month after KT.  The median time to 
the first UTI episode was 13 days (range: 5–29 days).  We did not observe any statistical 
difference in any other baseline characteristics in the KT recipients with and without UTI 
episodes in our cohort, except for sex.  Only the female sex presented as a significant risk 
factor for the incidence of UTI (p = 0.013).  The frequencies of each C1QA [276 A/G] 
(rs172378), FCGR2A [131 H/R] (rs1801274) and FCGR3A [158 F/V] (rs396991) genotype 
were compared with respect to post-operative outcomes (including UTIs) within 1 month 
after KT.  There were no differences in the incidence of CMV infections or fungal infections 
among all 3 genotype within 1 month after KT.  Notably, only the FCGR3A genotype was 
significantly associated with the incidence of UTI within 1 month of transplantation where 
FCGR3A [158 F/F or F/V] had more incidences of UTI than FCGR3A [158 V/V] (64.5% and 
35.5%, respectively) (p = 0.02).  Upon the univariate analysis of the baseline characteristic, 
female sex and the FCGR3A SNP were identified as significant risk factors for UTI.  The 
multivariate logistic regression analysis also identified those two independent factors that 
contributed significantly to the differences between the patients with and without UTI 
episodes within 1 month of transplantation (OR 3.53 [confidence interval (CI): 1.34–9.81], 
p = 0.009, and OR 3.26 [CI: 1.24–9.08], p = 0.015, respectively). 
As FcγR classes differ on the affinity for IgG subclasses and on the distribution among the 
immune cells, the combination of FCGR2A and FCGR3A SNPs probably can stratify the 
incidence of UTI.  Notably, we observed that the combination of the [158 V/V] genotype of 
FCGR3A along with the [131 R/R or H/R] genotype of FCGR2A showed a significantly lower 
incidence of UTI than the [158 F/F or F/V] genotype of FCGR3A and [131 H/H] genotype of 
FCGR2A (3/13, 23%: 16/27, 59%; p = 0.049). 
 Next, we adjusted the differences in the baseline characteristics by using the 
propensity scores and further examined the impact of FCGR3A SNP on post-transplant 
infectious complications within 1 month.  Five variables, including sex, ABO-blood type 
(ABO-compatible [ABO-C] and ABO-I), recipient and donor age, and treatment as dialysis 
and non-dialysis were used to calculate the propensity score of each patient.  Twenty-six 
patients with the FCGR3A [158 V/V] genotype were matched with same number of patients 
with the FCGR3A [158 F/F or F/V] genotype.  Among this one-to-one matched cohort, a 
significantly higher incidence of UTI was found in the patients with the FCGR3A [158 F/F or 
F/V] genotype than those with the FCGR3A [158 V/V] genotype (p = 0.004).  No statistical 
differences were observed with respect to the incidence of CMV or fungal infections between 
those variants.  Therefore, the FCGR3A F carrier may contribute to be the foremost risk 
factor for the occurrence of postoperative UTI within 1 month following KT.   
 In conclusion, the FCGR3A gene SNP in KT recipients was significantly associated 
with the susceptibility to post-transplant UTI.  This fact suggests that the 
immunosuppression therapy and antimicrobial surveillance can be adjusted by identifying 
the FcγR SNPs, leading to personalized medicine.   
